c-Met/HGFR

SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.

Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).

(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition for

Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6

BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe

Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.

Amivantamab (Anti-c-MET) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.

Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].

Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.

Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.

MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cell

Umikibart is a humanized IgG4κ antibody targeting HGF, with the corresponding isotype control being HumanIgG4(S228P) kappa, Isotype Control.

HGF-IN-1 is an inhibitor of HGF (Hepatocyte Growth Factor), and it can be utilized in cancer research.

SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.

BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.

AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.

ARGX-111 is a defucosylated anti-MET antibody that inhibits both HGF-dependent and HGF-independent signaling and reduces MET expression on tumor cell surfaces. It suppresses tumor metastasis by enhancing antibody-dependent cellular cytotoxicity (ADCC) to deplete MET-expressing circulating tumor cells. In metastatic breast cancer orthotopic mouse models, ARGX-111 has been shown to deplete circulating tumor cells and inhibit bone and lung metastases. This compound is suitable for research in cancers such as breast cancer.

SFN68 is a humanized IgG1 neutralizing monoclonal antibody targeting HGF. It significantly inhibits the interaction between HGF and c-Met, the activation of c-Met, and HGF-mediated cell scattering and proliferation. SFN68 is applicable for cancer research.

Tyrosine kinase-IN-4 (EXAMPLE 107) is a protein tyrosine kinase inhibitor [1].

Glesatinib is an orally active and potent dual inhibitor of MET/SMO.